Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in
Patients With Multiple Myeloma Examined in 2 Different Stages,
at Diagnosis and at Progression/Relapse

J 2016

Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse

MLYNARCIKOVA, Miroslava, Jana BALCARKOVA, Pavla MICKOVA, Vlastimil SCUDLA, Tomas PIKA et. al.

Základní údaje

Originální název

Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse

Autoři

MLYNARCIKOVA, Miroslava (203 Česká republika), Jana BALCARKOVA (203 Česká republika), Pavla MICKOVA (203 Česká republika), Vlastimil SCUDLA (203 Česká republika), Tomas PIKA (203 Česká republika), Jaroslav BACOVSKY (203 Česká republika), Jiri MINARIK (203 Česká republika), Eva JANOUŠOVÁ (203 Česká republika, garant, domácí) a Marie JAROSOVA (203 Česká republika)

Vydání

Clinical Lymphoma, Myeloma and Leukemia, Dallas, CIG Media Group, 2016, 2152-2650

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.494

Kód RIV

RIV/00216224:14110/16:00090553

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.clml.2016.02.038

UT WoS

000378029200011

Klíčová slova anglicky

FICTION; MYC; TRAIL-R1; TRAIL-R2; genetic changes

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 11. 2016 10:26, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

This retrospective study of 62 patients with multiple myeloma examined at 2 different phases (diagnosis and progression/relapse), revealed chromosome 8 aberrations in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. We did not confirm a significant increase of chromosome 8 aberrations at progression/relapse; however, we confirmed the heterogeneity of the aberrations and their poor prognostic impact on overall survival. Background: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. Patients and Methods: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. Results: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients. Conclusion: In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM.

Citovat

MLYNARCIKOVA, Miroslava, Jana BALCARKOVA, Pavla MICKOVA, Vlastimil SCUDLA, Tomas PIKA, Jaroslav BACOVSKY, Jiri MINARIK, Eva JANOUŠOVÁ a Marie JAROSOVA. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse. Clinical Lymphoma, Myeloma and Leukemia. Dallas: CIG Media Group, 2016, roč. 16, č. 6, s. 358-365. ISSN 2152-2650. Dostupné z: https://dx.doi.org/10.1016/j.clml.2016.02.038.

@article{1351369,
   author = {Mlynarcikova, Miroslava and Balcarkova, Jana and Mickova, Pavla and Scudla, Vlastimil and Pika, Tomas and Bacovsky, Jaroslav and Minarik, Jiri and Janoušová, Eva and Jarosova, Marie},
   article_location = {Dallas},
   article_number = {6},
   doi = {http://dx.doi.org/10.1016/j.clml.2016.02.038},
   keywords = {FICTION; MYC; TRAIL-R1; TRAIL-R2; genetic changes},
   language = {eng},
   issn = {2152-2650},
   journal = {Clinical Lymphoma, Myeloma and Leukemia},
   title = {Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse},
   volume = {16},
   year = {2016}
}

TY  - JOUR
ID  - 1351369
AU  - Mlynarcikova, Miroslava - Balcarkova, Jana - Mickova, Pavla - Scudla, Vlastimil - Pika, Tomas - Bacovsky, Jaroslav - Minarik, Jiri - Janoušová, Eva - Jarosova, Marie
PY  - 2016
TI  - Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse
JF  - Clinical Lymphoma, Myeloma and Leukemia
VL  - 16
IS  - 6
SP  - 358-365
EP  - 358-365
PB  - CIG Media Group
SN  - 21522650
KW  - FICTION
KW  - MYC
KW  - TRAIL-R1
KW  - TRAIL-R2
KW  - genetic changes
N2  - This retrospective study of 62 patients with multiple myeloma examined at 2 different phases (diagnosis and progression/relapse), revealed chromosome 8 aberrations in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. We did not confirm a significant increase of chromosome 8 aberrations at progression/relapse; however, we confirmed the heterogeneity of the aberrations and their poor prognostic impact on overall survival. Background: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. Patients and Methods: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. Results: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients. Conclusion: In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM.
ER  -

MLYNARCIKOVA, Miroslava, Jana BALCARKOVA, Pavla MICKOVA, Vlastimil SCUDLA, Tomas PIKA, Jaroslav BACOVSKY, Jiri MINARIK, Eva JANOUŠOVÁ a Marie JAROSOVA. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse. \textit{Clinical Lymphoma, Myeloma and Leukemia}. Dallas: CIG Media Group, 2016, roč.~16, č.~6, s.~358-365. ISSN~2152-2650. Dostupné z: https://dx.doi.org/10.1016/j.clml.2016.02.038.

Podrobný výpis o publikaci